American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Arix Bioscience to present at Jefferies 2017 Global Healthcare Conference in New York
LONDON, 31 May, 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "the Company"), a global healthcare and life science company supporting medical innovation, today announces that Joe Anderson, Chief Executive Officer of Arix Bioscience, will present at the Jefferies 2017 Global Healthcare Conference to be held on 6-8 June in New York, US.
The presentation will be on Thursday, 8 June at 4pm EDT and a webcast of the presentation will be available for 90 days on the conference website.
Additionally, a number of Arix's Group Businesses will be present at the conference, including:
Jan-Anders Karlsson, Chief Executive Officer of Verona Pharma plc, will present on Thursday, 8 June at 11.30am EDT. Verona Pharma is a listed clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet needs.
The management team at Autolus Ltd will attend the conference and will be available for 1-1 meetings. Autolus is a private biopharmaceutical company focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology.
For more information, please contact:
Arix Bioscience plc
Joe Anderson, CEO
+44 (0) 20 7290 1052
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
[email protected]
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.
For further information, please visit www.arixbioscience.com
